Drug Discovery & Development |
GSK, Theravance asthma drug shows improved lung function in study
Reuters The drug, already approved in the U.S. to treat chronic obstructive pulmonary disease (COPD) under the brand name Breo, proved more effective than fluticasone furoate alone for patients with moderate to severe asthma at the end of a 12-week treatment … GSK, Theravance Report Positive Results For FF/VI In Late Stage Asthma Study Theravance and Glaxo say asthma study succeeded |
View full post on asthma – Google News